Overall, our findings confirm the principal role for ISG15 as a positive regulator of type I IFN signaling by facilitating STAT1 and STAT2 activation and nuclear translocation, which provide a viable option for developing therapeutic target for controlling PRV. This evidence concerns the gene ISG15 and acquired polycythemia vera.